In its May 2026 quarterly filing, Humacyte implemented a workforce reduction of about 45 employees and deferred new hiring as part of cost-saving efforts to extend cash runway. The company also realigned distribution rights for its Symvess acellular tissue engineered vessels (ATEVs), reclaiming worldwide commercialization control while agreeing to low single-digit royalties to Fresenius outside the U.S. These moves come against a backdrop of continued net losses, liquidity management focus, and active regulatory pursuits in markets like Israel and Saudi Arabia. The company faces material risks including potential Nasdaq delisting due to share price non-compliance, posing challenges for capital access and operational execution.